Periaqueductal Gray In Analgesia is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The periaqueductal gray (PAG) is a midbrain structure that serves as the central hub for endogenous pain modulation and represents a critical interface between emotional and sensory aspects of pain processing.
| Property |
Value |
| Category |
Pain Modulation |
| Location |
Midbrain, surrounding the cerebral aqueduct |
| Cell Type |
Mixed neuronal populations (glutamatergic, GABAergic, serotonergic) |
| Function |
Endogenous pain control, opioid-mediated analgesia |
The PAG is organized into four longitudinal columns that subserve distinct functions:
- ** dorsolateral/lateral column (lPAG) **: Processes somatic and visceral pain, activates defensive behaviors
- ** ventrolateral column (vlPAG) **: Mediates opioid analgesia, fear freezing, and autonomic regulation
- ** dorsomedial column (dmPAG) **: Associates with aversion and panic responses
- ** lateral/dorsolateral (lateral PAG) **: Coordinates pain modulation with motor outputs
The PAG receives dense projections from:
- Spinal cord dorsal horn (pain signals)
- Hypothalamus (emotional and autonomic integration)
- Amygdala (fear and emotional pain)
- Prefrontal cortex (cognitive pain modulation)
- Parabrachial nucleus (visceral sensory information)
Descending projections from the PAG target:
- Rostral ventromedial medulla (RVM)
- Dorsal horn of the spinal cord
- Nucleus tractus solitarius (NTS)
- Locus coeruleus (noradrenergic pain modulation)
The PAG contains high concentrations of endogenous opioids including:
- Enkephalins: Met- and Leu-enkephalin
- Endorphins: β-endorphin from periaqueductal neurons
- Dynorphins: Found in specific subpopulations
Opioid receptor activation (primarily μ-opioid receptors) hyperpolarizes PAG neurons via G-protein mediated potassium channel opening, reducing GABAergic inhibition of output neurons and enabling descending inhibition.
- Serotonin (5-HT): PAG 5-HT neurons project to RVM and spinal cord
- Norepinephrine: Co-released from locus coeruleus projections
- Both contribute to non-opioid analgesic mechanisms
- Glutamate: Acts via NMDA and AMPA receptors
- Substance P: Co-transmitter in pain pathways
- CGRP: Calcitonin gene-related peptide in migraine mechanisms
The PAG-RVM-spinal cord axis operates as a bidirectional system:
Inhibition Pathway:
- Noxious stimuli activate PAG neurons
- PAG projects to RVM
- RVM sends serotonergic and noradrenergic fibers to dorsal horn
- Released 5-HT and NE inhibit dorsal horn nociceptive transmission
Facilitation (when maladaptive):
- Prolonged pain can shift PAG-RVM function to facilitation
- Contributes to chronic pain states
- May underlie opioid-induced hyperalgesia
The PAG plays a central role in migraine pathophysiology:
- Dysfunctional Descending Inhibition: Reduced PAG activity in chronic migraineurs
- Brainstem Aura: Nucleus cuneiformis and PAG activation correlate with migraine aura
- Triptan Mechanism: 5-HT1B/1D agonists may act partially through PAG modulation
- Allodynia: Central sensitization involves PAG-RVM facilitation
- Fibromyalgia: Reduced PAG gray matter volume and altered functional connectivity
- Chronic Daily Headache: Abnormal PAG resting state activity
- Neuropathic Pain: Loss of PAG-mediated inhibition
- Tolerance Development: Chronic opioid exposure reduces PAG analgesic efficacy
- Physical Dependence: PAG opioid receptor downregulation contributes
- Opioid-induced Hyperalgesia: Paradoxical pain sensitization via PAG mechanisms
- Withdrawal: PAG hyperactivity contributes to withdrawal symptoms
- PAG dysfunction contributes to non-motor symptoms
- Pain processing alterations in PD patients
- Deep brain stimulation effects may involve PAG modulation
- PAG receives cholinergic projections from pedunculopontine nucleus
- Cholinergic loss in AD may impair PAG-mediated analgesia
- Pain detection deficits in advanced AD may involve PAG
- Respiratory dysfunction involves medullary respiratory centers
- PAG contributes to automatic breathing control
- Dysautonomia in ALS includes PAG-mediated functions
- PAG-DBS investigated for refractory pain
- May restore descending inhibition balance
- μ-opioid agonists: Morphine, fentanyl (PAG-mediated)
- Serotonin-norepinephrine reuptake inhibitors: Duloxetine (enhance descending inhibition)
- Gabapentinoids: Modulate PAG-RVM axis
- Transcranial Magnetic Stimulation: Can modulate PAG activity
- Meditation/Mindfulness: Increases PAG functional connectivity
- fMRI: Pain-induced PAG activation
- PET: Opioid receptor binding studies
- Lesion Studies: PAG role in analgesia
- Optogenetics: Circuit-specific manipulation
The study of Periaqueductal Gray In Analgesia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Behbehani MM. Functional characteristics of the midbrain periaqueductal gray Prog Neurobiol. 1995.
- Bandler R, Keay KA. Columnar organization in the midbrain periaqueductal gray Trends Neurosci. 2000.
- Fields HL. Pain modulation: expectation, opioid analgesia and virtual pain Prog Brain Res. 2000.
- Millan MJ. Descending control of pain Prog Neurobiol. 2002.
- Cao J, et al. Periaqueductal gray opioid receptor subtype switching and morphine tolerance Neurosci Bull. 2019.
- Watson A, et al. Functional connectivity of the human periaqueductal gray during pain Hum Brain Mapp. 2017.